The FDA recently ruled bluebird bio’s blood disorder therapy as effective, and William Blair analyst Raju Prasad is quoted on the implications for the company.
Equity Research
William Blair Analyst Raju Prasad Comments on Bluebird Bio in Reuters
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
Contineum Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Contineum Therapeutics, Inc. (CTNM $3.93), a clinical-stage biotech developing small-molecule therapeutics for high-unmet-need indications in the prevalent neuroinflammation and immunology space.
-
-